Drug Trial Radar · NCT01340482
A Repeated Study of KRN23 in Adults With X-Linked Hypophosphatemia
Last checked: Nov 20, 2026Latest source record: Jun 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Apr 2011
Primary completion
May 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Kyowa Kirin Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the safety and efficacy of repeated subcutaneous (SC) injections of KRN23 in adult subjects with X-Linked Hypophosphatemia (XLH). A Bone Substudy will evaluate the effects of single-blind KRN23 versus Placebo on bone mineral density and bone quality.
Conditions
- X-linked Hypophosphatemia
Interventions
KRN23Drug
Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Efficacy of Repeated SC Injections of KRN23Time frame: On-Treatment: 6.5 months, 27 total visits
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
University of California, San Francisco Medical Center
San Francisco, California
Yale University School of Medicine
New Haven, Connecticut
Clinical Research Center, Indiana University School of Medicine
Indianapolis, Indiana
Duke Clinical Research Unit
Durham, North Carolina
University of Texas Health Science Center at Houston
Houston, Texas
Shriners Hospital for Children - Canada
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.